Test Price
2,800 AED✅ Home Collection Available
LMNA Gene Restrictive Dermopathy, Lethal Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
This advanced genetic diagnostic solution, licensed by the Dubai Health Authority, delivers 99.9% accuracy in identifying lethal mutations in the LMNA gene causing restrictive dermopathy. We provide premium logistics including VIP mobile phlebotomy and temperature-controlled home collection, with immediate clinical support from a DHA-licensed consultant.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed Consultant Medical Geneticist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This LMNA gene next-generation sequencing test is essential for neonatal diagnosis, carrier detection, and recurrence risk assessment of lethal restrictive dermopathy. Our NGS platform provides full-gene coverage, detecting nucleotide-level mutations with exceptional precision.
| Feature | Our Test (DNA Labs UAE) | Closest Alternative |
|---|---|---|
| Precision | 99.9% diagnostic sensitivity, full LMNA gene coverage (NGS) | Sanger sequencing of selected exons; may miss deep intronic variants |
| Methodology | NGS (Next‑Generation Sequencing) – simultaneous analysis of all coding regions | Conventional PCR‑Sanger, limited to known hot‑spots |
| Turnaround Time | 3‑4 weeks | Often 6‑8 weeks |
Relevant Specialists: Dermatologist (clinical evaluation of skin fragility), Clinical Geneticist (NGS variant interpretation & genetic counselling), Neonatologist (management of lethal neonatal phenotype).
Physician Insight & Safety Protocols
“As a Consultant Medical Geneticist, I understand the profound anxiety families face when confronted with a suspected lethal genetic disorder. Our NGS panel provides critical genetic confirmation for accurate diagnosis, recurrence risk assessment, and family planning. I urge all patients to discuss results with a genetic counselor before making any clinical decisions.”
— Lina Osama Zaki Quteineh, DHA License: 9294403
⚠️ Important Advisory
Do not discontinue prescribed medication without consulting your doctor. Genetic testing results should only be used in conjunction with comprehensive clinical evaluation.
Patient Exclusion Criteria & Emergency Red Flags
- Sample not viable (gross hemolysis, insufficient volume, improper FTA card saturation).
- Inability to provide clinical history or family pedigree chart (required for accurate interpretation).
- Emergency Red Flags: Newborn with severe skin blistering, respiratory distress, or contractures – seek immediate emergency care; do not delay for test results.
- Genetic testing in minors must comply with parental/legal guardian consent and ethical guidelines.
Patient FAQ & Clinical Guidance
1. What is the LMNA gene test used for?
The LMNA Genetic Test is a targeted sequencing analysis designed to detect nucleotide-level mutations in the entire LMNA gene, providing definitive diagnosis of lethal restrictive dermopathy and enabling accurate genetic counselling.
2. How accurate is this Genetic Test?
Our ISO-certified LMNA NGS assay achieves 99.9% diagnostic sensitivity through full-gene coverage and rigorous variant calling pipelines, virtually eliminating false-negative results in lethal restrictive dermopathy.
3. What is the turnaround time and sample requirements?
Turnaround time is 3-4 weeks from receipt of a whole blood, extracted DNA, or FTA card sample. Home collection service is available daily from 8 AM to 11 PM via VIP mobile phlebotomy.
UAE Regulatory & Data Privacy Adherence
Compliance Framework
This service strictly adheres to:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensuring patient data confidentiality and security.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – regulating digital health data handling.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – defining clinical safety and patient consent standards.
All genetic counselling sessions and consent procedures are conducted in accordance with UAE medical ethics and best practices.
Clinical & Logistical Metadata
| Test Name | LMNA Gene Restrictive Dermopathy, Lethal Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3-4 weeks |
| Sample Type / Matrix | Whole blood (EDTA), extracted DNA, or FTA card (dried blood spot) |
| Methodology Used | Next-Generation Sequencing (NGS) – full gene coverage |
| ICD-10-CM Code | Q82.8, Z15.89, Z14.8 |
| LOINC Code | 94246-0 |
| DHA Facility License & Laboratory Address | Licence: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians